NCT05629741View on ClinicalTrials.gov

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

August 2, 2024

Study Completion Date

August 2, 2024

Conditions
Community-acquired PneumoniaBacterial Pneumonia
Interventions
DRUG

CMTX-101

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (8)

14215

Buffalo VA Medical Center, Buffalo

22908

University of Virginia School of Medicine, Charlottesville

30912

Augusta University Health, Augusta

40292

University of Louisville, Louisville

43210

The Ohio State University, Columbus

45227

Medpace Clinical Pharmacology Unit, Cincinnati

48202

Wayne State University, Detroit

83404

Snake River Research, PLLC, Idaho Falls

Sponsors
All Listed Sponsors
lead

Clarametyx Biosciences, Inc.

INDUSTRY

NCT05629741 - A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 | Biotech Hunter | Biotech Hunter